Vickie Lin

Senior Director
20+ years of international tax experience   
Focuses on supply chain, M&A, divestitures and restructuring
Delivers end-to-end solutions for wide range of tax issues
Houston
@alvarezmarsal
LinkedIn
Copied!
Vickie Lin is a Senior Director with Alvarez & Marsal Tax in Houston. She brings more than 20 years of experience in international tax related to supply chain, M&A, divestitures and restructuring.

Ms. Lin specializes in aligning tax and legal structures with evolving business operating models, including organic global expansion, acquisition integration, and business realignment. 

Ms. Lin delivers practical, end-to-end solutions for a broad spectrum of tax issues such as corporate income tax, indirect tax, individual income tax, global trade, transfer pricing, tax controversy and financial incentives, and considers other business functions including treasury, legal, government relationship, supply chain, manufacturing, R&D, sales, IT and HR.

Major projects Ms. Lin has worked on include global/regional centralized procurement models, global/regional principal/hub, local-for-local country supply chain models, divesture and integration of post-acquisition structures. She has worked with clients in various industries, including consumer products, automotive, manufacturing, life sciences, financial services, technology and telecommunications.

Prior to joining A&M, Ms. Lin spent over 20 years in Big Four public accounting.

Ms. Lin earned an MBA from New York University. 

.

Latest insights The latest insights from Vickie Lin's team
Thought Leadership
Effective July 31, 2026, the additional Section 232 tariff on patented pharmaceuticals that are products of the United Kingdom was reduced from 10% to zero (heading 9903.04.63), implementing the U.S.–UK Pharmaceutical Pricing Arrangement. Because UK patented pharmaceuticals remain subject to Section 232 (at a 0% rate), they also fall within the Section 232 carve-out from the new Section 301 forced labor tariffs — so qualifying UK patented product should face no additional duty under either regime.